{"hands_on_practices": [{"introduction": "A cornerstone of personalized medicine is adjusting drug dosage based on individual patient physiology. For many DMARDs, such as methotrexate, renal function is a primary determinant of drug elimination. This exercise [@problem_id:4531820] provides fundamental practice in using a physiological marker, creatinine clearance ($CrCl$), within a population pharmacokinetic model to calculate a patient-specific dose, ensuring that drug exposure remains within the target therapeutic window despite impaired organ function.", "problem": "A patient with rheumatoid arthritis is being treated with low-dose oral methotrexate, a Disease-Modifying Anti-Rheumatic Drug (DMARD). Assume linear, time-invariant pharmacokinetics with first-order elimination and immediate absorption, and an oral bioavailability $F$. In a population pharmacokinetic model, methotrexate total clearance $CL$ scales with creatinine clearance (CrCl) according to $CL = \\theta \\times \\text{CrCl}$, with $\\text{CrCl}$ expressed in $\\text{L/h}$ and $\\theta$ a dimensionless proportionality constant derived from the population model. The target average steady-state plasma concentration over the weekly dosing interval, $C_{\\text{avg,target}}$, is specified by the clinical protocol. The dosing interval is $\\tau$.\n\nFor a patient with moderate renal impairment (Creatinine Clearance, $\\text{CrCl} = 45\\,\\text{mL/min}$), use the following parameter values: $\\theta = 1.2$, $F = 0.70$, $\\tau = 168\\,\\text{h}$, and $C_{\\text{avg,target}} = 0.009\\,\\text{mg/L}$. Under the above assumptions and using the population clearance model, determine the single weekly dose (in $\\text{mg/week}$) that maintains the target $C_{\\text{avg}}$ in this patient. Round your final dose to two significant figures and express your answer in $\\text{mg/week}$.", "solution": "The problem statement is first validated according to the specified procedure.\n\n### Step 1: Extract Givens\n- **Pharmacokinetic Model**: Linear, time-invariant pharmacokinetics, first-order elimination, immediate absorption.\n- **Drug and Patient Population**: Low-dose oral methotrexate for a patient with rheumatoid arthritis.\n- **Oral Bioavailability**: $F$.\n- **Total Clearance**: $CL$.\n- **Creatinine Clearance**: $\\text{CrCl}$.\n- **Clearance Model**: $CL = \\theta \\times \\text{CrCl}$, where $\\text{CrCl}$ is in units of $\\text{L/h}$.\n- **Proportionality Constant**: $\\theta$, dimensionless.\n- **Target Concentration**: $C_{\\text{avg,target}}$, target average steady-state plasma concentration over the dosing interval.\n- **Dosing Interval**: $\\tau$.\n- **Patient-Specific Data**:\n    - Creatinine Clearance, $\\text{CrCl} = 45\\,\\text{mL/min}$.\n- **Model Parameter Values**:\n    - $\\theta = 1.2$.\n    - $F = 0.70$.\n    - $\\tau = 168\\,\\text{h}$.\n    - $C_{\\text{avg,target}} = 0.009\\,\\text{mg/L}$.\n- **Objective**: Determine the single weekly dose in $\\text{mg/week}$.\n- **Rounding Requirement**: Round the final dose to two significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is well-grounded in the principles of clinical pharmacokinetics. The use of a linear, one-compartment model with first-order elimination is a standard and widely accepted simplification for dosage calculations. The relationship between drug clearance ($CL$) and a physiological marker of renal function (creatinine clearance, $\\text{CrCl}$) is a cornerstone of dose adjustment for drugs eliminated by the kidneys, such as methotrexate. The model $CL = \\theta \\times \\text{CrCl}$ is a valid, simplified representation of a population pharmacokinetic model. The provided parameter values are clinically plausible.\n- **Well-Posed**: The problem is well-posed, providing all necessary parameters and a clear objective. There is a unique solution derivable from the provided information.\n- **Objective**: The problem is stated using precise, quantitative, and objective language, free of ambiguity or subjective claims.\n- **Other Flaws**: The problem is free of the flaws listed in the validation criteria. It is complete, consistent, realistic, and directly pertains to the specified topic, *clinical pharmacology of disease-modifying antirheumatic drugs (DMARDs)*.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A solution will be provided.\n\n### Solution Derivation\nThe fundamental principle for determining the maintenance dose is based on the concept of steady-state, where the rate of drug administration is equal to the rate of drug elimination. For a drug administered orally, the average plasma concentration at steady-state, $C_{\\text{avg,ss}}$, is given by the ratio of the rate of drug entering the systemic circulation to the total body clearance of the drug.\n\nThe rate of drug entering the systemic circulation is the dosing rate ($\\frac{\\text{Dose}}{\\tau}$) multiplied by the oral bioavailability ($F$). The equation is:\n$$C_{\\text{avg,ss}} = \\frac{\\text{Rate of drug absorption}}{\\text{Clearance}} = \\frac{\\frac{\\text{Dose} \\times F}{\\tau}}{CL}$$\nThis can be rearranged to solve for the dose:\n$$\\text{Dose} = \\frac{C_{\\text{avg,ss}} \\times CL \\times \\tau}{F}$$\n\nIn this problem, the clinical goal is to achieve a target average steady-state concentration, $C_{\\text{avg,target}}$. Therefore, we set $C_{\\text{avg,ss}} = C_{\\text{avg,target}}$.\n$$\\text{Dose} = \\frac{C_{\\text{avg,target}} \\times CL \\times \\tau}{F}$$\n\nThe problem provides a population model to estimate the patient's total clearance, $CL$, from their creatinine clearance, $\\text{CrCl}$:\n$$CL = \\theta \\times \\text{CrCl}$$\n\nThe provided value for $\\text{CrCl}$ is $45\\,\\text{mL/min}$. The model requires $\\text{CrCl}$ to be in units of $\\text{L/h}$. A unit conversion is necessary.\nGiven $1\\,\\text{L} = 1000\\,\\text{mL}$ and $1\\,\\text{h} = 60\\,\\text{min}$:\n$$\\text{CrCl} = 45\\,\\frac{\\text{mL}}{\\text{min}} \\times \\frac{1\\,\\text{L}}{1000\\,\\text{mL}} \\times \\frac{60\\,\\text{min}}{1\\,\\text{h}} = \\frac{45 \\times 60}{1000}\\,\\frac{\\text{L}}{\\text{h}} = 2.7\\,\\frac{\\text{L}}{\\text{h}}$$\n\nNow, we can calculate the patient's total clearance, $CL$, using the provided value of $\\theta = 1.2$:\n$$CL = 1.2 \\times 2.7\\,\\frac{\\text{L}}{\\text{h}} = 3.24\\,\\frac{\\text{L}}{\\text{h}}$$\n\nWith all parameters determined, we can calculate the required weekly dose. The given parameters are:\n- $C_{\\text{avg,target}} = 0.009\\,\\text{mg/L}$\n- $CL = 3.24\\,\\text{L/h}$\n- $\\tau = 168\\,\\text{h}$\n- $F = 0.70$\n\nSubstituting these values into the dose equation:\n$$\\text{Dose} = \\frac{(0.009\\,\\frac{\\text{mg}}{\\text{L}}) \\times (3.24\\,\\frac{\\text{L}}{\\text{h}}) \\times (168\\,\\text{h})}{0.70}$$\n\nFirst, calculate the numerator:\n$$\\text{Numerator} = 0.009 \\times 3.24 \\times 168 = 4.89888\\,\\text{mg}$$\nThe units are consistent: $\\frac{\\text{mg}}{\\text{L}} \\times \\frac{\\text{L}}{\\text{h}} \\times \\text{h} = \\text{mg}$.\n\nNow, divide by the bioavailability, $F$:\n$$\\text{Dose} = \\frac{4.89888\\,\\text{mg}}{0.70} \\approx 6.9984\\,\\text{mg}$$\n\nThe problem requires the answer to be rounded to two significant figures. The calculated dose is approximately $6.9984\\,\\text{mg}$.\nThe first significant figure is $6$.\nThe second significant figure is $9$.\nThe third digit is $9$, which is $\\ge 5$, so we round up the second significant figure. Rounding $9$ up results in $0$ and carrying over $1$ to the preceding digit.\nThus, $6.9...$ rounds up to $7.0$. The trailing zero is significant.\n\nThe required weekly dose is $7.0\\,\\text{mg}$.", "answer": "$$\n\\boxed{7.0}\n$$", "id": "4531820"}, {"introduction": "Polypharmacy is common in patients with rheumatoid arthritis, making drug-drug interactions (DDIs) a critical consideration. Targeted synthetic DMARDs, like tofacitinib, are often substrates for multiple metabolic enzymes (such as CYP3A4) and drug transporters (such as P-gp). This problem [@problem_id:4531761] challenges you to integrate multiple DDI mechanisms—simultaneously affecting both systemic clearance and oral bioavailability—to determine the necessary dose adjustments, highlighting the importance of a holistic view of pharmacokinetics in complex therapeutic regimens.", "problem": "A patient with rheumatoid arthritis is maintained on immediate-release tofacitinib, a Janus kinase inhibitor classified among targeted synthetic disease-modifying antirheumatic drugs, at a dosing regimen of $5\\,\\mathrm{mg}$ every $12\\,\\mathrm{h}$. Tofacitinib disposition is described by linear pharmacokinetics and low hepatic extraction. Its systemic clearance is composed of a renal component and metabolic components, with cytochrome P450 3A4 (CYP3A4) being the dominant metabolic pathway. Tofacitinib is also a substrate of P-glycoprotein (P-gp), which modulates the intestinal escape fraction and thus oral bioavailability. Assume the following baseline parameters: baseline oral bioavailability $F_{0} = 0.70$ (dimensionless), baseline systemic clearance $CL_{0} = 24\\,\\mathrm{L\\,h^{-1}}$, and fractional contributions to systemic clearance $f_{\\mathrm{CYP3A4}} = 0.60$, $f_{\\mathrm{renal}} = 0.30$, and $f_{\\mathrm{other}} = 0.10$. Assume the hepatic first-pass effect is negligible under the low-extraction assumption, so changes in metabolic intrinsic clearance do not materially alter hepatic first-pass availability. Consider two coadministrations:\n\n1. Ketoconazole, a strong inhibitor of CYP3A4 and P-gp, reduces the CYP3A4-mediated intrinsic clearance to $10\\%$ of its baseline value and increases the effective oral bioavailability via P-gp inhibition by a factor of $1.25$ relative to baseline (i.e., new $F$ is $1.25 \\times F_{0}$). All other clearance pathways are unchanged.\n\n2. Rifampin, a strong inducer of CYP3A4 and P-gp, increases the CYP3A4-mediated intrinsic clearance by a factor of $4.0$ relative to baseline (i.e., new CYP3A4 clearance is $4.0$ times baseline) and decreases the effective oral bioavailability via P-gp induction by a factor of $0.60$ relative to baseline (i.e., new $F$ is $0.60 \\times F_{0}$). All other clearance pathways are unchanged.\n\nStarting from core definitions for linear pharmacokinetics, conservation of mass, and pathway-specific contributions to total systemic clearance, first derive expressions that relate the steady-state exposure over a dosing interval $\\tau = 12\\,\\mathrm{h}$ to the dose, oral bioavailability, and systemic clearance, and show how coadministration alters the apparent oral clearance through simultaneous changes in CYP3A4-mediated metabolic clearance and P-gp-modulated bioavailability. Then compute the adjusted tofacitinib doses that would maintain the same steady-state average concentration over the dosing interval as at baseline when coadministered with ketoconazole or with rifampin, assuming $\\tau$ remains $12\\,\\mathrm{h}$ and that renal and non-CYP clearance components are unaffected by the perpetrators.\n\nExpress each adjusted dose in milligrams, and round your final numeric answers to three significant figures. Provide your final answer as a two-element row in the order $\\big[$ketoconazole-adjusted dose, rifampin-adjusted dose$\\big]$.", "solution": "The problem is a well-posed application of fundamental pharmacokinetic principles to a clinical drug-drug interaction scenario. It is scientifically grounded, internally consistent, and contains all necessary information to derive a unique solution. Therefore, the problem is valid.\n\nThe core principle for a drug administered orally under linear pharmacokinetic conditions at steady state is that the average rate of drug administration equals the average rate of drug elimination over a dosing interval, $\\tau$. The average steady-state plasma concentration, $C_{\\mathrm{ss,avg}}$, is defined by this balance.\n\nThe amount of drug that becomes systemically available from an oral dose $D$ is given by $F \\times D$, where $F$ is the oral bioavailability. The average rate of drug input into the systemic circulation is thus $\\frac{F \\times D}{\\tau}$.\n\nThe rate of elimination from the body is proportional to the plasma concentration, $C(t)$, and the constant of proportionality is the total systemic clearance, $CL$. The average rate of elimination at steady state is $CL \\times C_{\\mathrm{ss,avg}}$.\n\nEquating the average rates of input and elimination gives:\n$$CL \\times C_{\\mathrm{ss,avg}} = \\frac{F \\times D}{\\tau}$$\nThis can be rearranged to solve for the average steady-state concentration:\n$$C_{\\mathrm{ss,avg}} = \\frac{F \\times D}{CL \\times \\tau}$$\nThe total drug exposure over one dosing interval at steady state is the Area Under the Curve, $AUC_{\\tau,ss}$. It is related to the average concentration by $C_{\\mathrm{ss,avg}} = \\frac{AUC_{\\tau,ss}}{\\tau}$. Substituting this into the previous equation yields the fundamental relationship for exposure:\n$$AUC_{\\tau,ss} = \\frac{F \\times D}{CL}$$\nThe problem requires finding an adjusted dose, $D_{\\mathrm{adj}}$, that maintains the same average steady-state concentration as the baseline condition when a drug is coadministered. Let the baseline parameters be denoted with a subscript $0$ and the adjusted parameters with a subscript $\\mathrm{adj}$. The condition to be met is $C_{\\mathrm{ss,avg,adj}} = C_{\\mathrm{ss,avg},0}$.\n$$\\frac{F_{\\mathrm{adj}} \\times D_{\\mathrm{adj}}}{CL_{\\mathrm{adj}} \\times \\tau} = \\frac{F_0 \\times D_0}{CL_0 \\times \\tau}$$\nSince the dosing interval $\\tau$ remains unchanged, it cancels out. We can solve for the adjusted dose, $D_{\\mathrm{adj}}$:\n$$D_{\\mathrm{adj}} = D_0 \\times \\left(\\frac{F_0}{F_{\\mathrm{adj}}}\\right) \\times \\left(\\frac{CL_{\\mathrm{adj}}}{CL_0}\\right)$$\nThis equation shows that the dose must be adjusted by a factor that accounts for the fold-change in bioavailability and the fold-change in total systemic clearance. The term $CL/F$ is known as the apparent oral clearance. The dose adjustment factor is the ratio of the new apparent oral clearance to the old one: $D_{\\mathrm{adj}} / D_0 = (CL_{\\mathrm{adj}}/F_{\\mathrm{adj}}) / (CL_0/F_0)$.\n\nNext, we must determine how the coadministered drugs alter $F$ and $CL$. Total systemic clearance, $CL$, is the sum of all parallel elimination pathway clearances. From the problem statement:\n$$CL = CL_{\\mathrm{renal}} + CL_{\\mathrm{CYP3A4}} + CL_{\\mathrm{other}}$$\nThe baseline values for these partial clearances can be calculated from the baseline total clearance, $CL_0 = 24\\,\\mathrm{L\\,h^{-1}}$, and the given fractional contributions:\n$CL_{\\mathrm{CYP3A4},0} = f_{\\mathrm{CYP3A4}} \\times CL_0 = 0.60 \\times 24\\,\\mathrm{L\\,h^{-1}} = 14.4\\,\\mathrm{L\\,h^{-1}}$\n$CL_{\\mathrm{renal},0} = f_{\\mathrm{renal}} \\times CL_0 = 0.30 \\times 24\\,\\mathrm{L\\,h^{-1}} = 7.2\\,\\mathrm{L\\,h^{-1}}$\n$CL_{\\mathrm{other},0} = f_{\\mathrm{other}} \\times CL_0 = 0.10 \\times 24\\,\\mathrm{L\\,h^{-1}} = 2.4\\,\\mathrm{L\\,h^{-1}}$\n\nThe problem states that only the CYP3A4-mediated clearance is affected by the coadministered drugs. The new total clearance, $CL_{\\mathrm{adj}}$, will be the sum of the altered CYP3A4 clearance and the unchanged renal and other clearances.\n$$CL_{\\mathrm{adj}} = CL_{\\mathrm{CYP3A4,adj}} + CL_{\\mathrm{renal},0} + CL_{\\mathrm{other},0}$$\n\nLet's analyze each coadministration scenario.\n\n**1. Coadministration with Ketoconazole (inhibitor)**\n\nKetoconazole reduces the CYP3A4-mediated clearance to $10\\%$ of its baseline value and increases bioavailability by a factor of $1.25$.\n- New bioavailability: $F_k = 1.25 \\times F_0$. Therefore, the ratio $\\frac{F_0}{F_k} = \\frac{1}{1.25} = 0.8$.\n- New CYP3A4 clearance: $CL_{\\mathrm{CYP3A4},k} = 0.10 \\times CL_{\\mathrm{CYP3A4},0}$.\n- New total clearance, $CL_k$:\n$$CL_k = (0.10 \\times CL_{\\mathrm{CYP3A4},0}) + CL_{\\mathrm{renal},0} + CL_{\\mathrm{other},0}$$\nWe can express the ratio $CL_k/CL_0$ in terms of the fractional contributions:\n$$\\frac{CL_k}{CL_0} = \\frac{(0.10 \\times f_{\\mathrm{CYP3A4}} \\times CL_0) + (f_{\\mathrm{renal}} \\times CL_0) + (f_{\\mathrm{other}} \\times CL_0)}{CL_0}$$\n$$\\frac{CL_k}{CL_0} = 0.10 \\times f_{\\mathrm{CYP3A4}} + f_{\\mathrm{renal}} + f_{\\mathrm{other}}$$\nSubstituting the given values:\n$$\\frac{CL_k}{CL_0} = 0.10 \\times 0.60 + 0.30 + 0.10 = 0.06 + 0.30 + 0.10 = 0.46$$\nNow we compute the adjusted dose, $D_k$, using the baseline dose $D_0 = 5\\,\\mathrm{mg}$:\n$$D_k = D_0 \\times \\left(\\frac{F_0}{F_k}\\right) \\times \\left(\\frac{CL_k}{CL_0}\\right) = 5\\,\\mathrm{mg} \\times (0.8) \\times (0.46) = 1.84\\,\\mathrm{mg}$$\nRounding to three significant figures, the adjusted dose is $1.84\\,\\mathrm{mg}$.\n\n**2. Coadministration with Rifampin (inducer)**\n\nRifampin increases the CYP3A4-mediated clearance by a factor of $4.0$ and decreases bioavailability by a factor of $0.60$.\n- New bioavailability: $F_r = 0.60 \\times F_0$. Therefore, the ratio $\\frac{F_0}{F_r} = \\frac{1}{0.60}$.\n- New CYP3A4 clearance: $CL_{\\mathrm{CYP3A4},r} = 4.0 \\times CL_{\\mathrm{CYP3A4},0}$.\n- New total clearance, $CL_r$:\n$$CL_r = (4.0 \\times CL_{\\mathrm{CYP3A4},0}) + CL_{\\mathrm{renal},0} + CL_{\\mathrm{other},0}$$\nThe ratio $CL_r/CL_0$ is:\n$$\\frac{CL_r}{CL_0} = 4.0 \\times f_{\\mathrm{CYP3A4}} + f_{\\mathrm{renal}} + f_{\\mathrm{other}}$$\nSubstituting the given values:\n$$\\frac{CL_r}{CL_0} = 4.0 \\times 0.60 + 0.30 + 0.10 = 2.40 + 0.30 + 0.10 = 2.80$$\nNow we compute the adjusted dose, $D_r$:\n$$D_r = D_0 \\times \\left(\\frac{F_0}{F_r}\\right) \\times \\left(\\frac{CL_r}{CL_0}\\right) = 5\\,\\mathrm{mg} \\times \\left(\\frac{1}{0.60}\\right) \\times (2.80) = 5\\,\\mathrm{mg} \\times \\frac{2.80}{0.60} \\approx 23.333...\\,\\mathrm{mg}$$\nRounding to three significant figures, the adjusted dose is $23.3\\,\\mathrm{mg}$.\n\nThe final answers are the adjusted doses for coadministration with ketoconazole and rifampin, respectively.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n1.84 & 23.3\n\\end{pmatrix}\n}\n$$", "id": "4531761"}, {"introduction": "The advent of biologic DMARDs, particularly monoclonal antibodies, introduced new challenges in clinical pharmacology, including the potential for immunogenicity. The development of anti-drug antibodies (ADAs) can significantly increase a biologic's clearance, potentially leading to a loss of response. This practice [@problem_id:4531849] shifts the focus from dose calculation to predicting the clinical consequence of such a pharmacokinetic change, requiring you to determine the impact of ADA-mediated clearance on steady-state trough concentrations, a crucial skill for interpreting therapeutic drug monitoring data for biologics.", "problem": "A patient with rheumatoid arthritis is treated with a fully human immunoglobulin G1 monoclonal antibody disease-modifying antirheumatic drug (DMARD) administered subcutaneously at a fixed dose and fixed dosing interval. At steady state prior to the development of anti-drug antibodies (ADAs), the measured trough concentration is $7.20$ mg/L. After several months, ADAs develop and increase the drug’s systemic clearance by 25% relative to baseline, with no change in dosing regimen, bioavailability, or the within-interval concentration–time shape factor that links the trough concentration to the average steady-state concentration. Assume linear pharmacokinetics.\n\nUsing only fundamental definitions of clearance and steady-state mass balance, determine the new steady-state trough concentration. Express your final answer in mg/L and round to three significant figures.", "solution": "The problem will first be validated to ensure it is scientifically sound, well-posed, and objective.\n\n### Step 1: Extract Givens\n- **Drug type:** Fully human immunoglobulin G1 monoclonal antibody disease-modifying antirheumatic drug (DMARD).\n- **Administration:** Subcutaneous, fixed dose, fixed dosing interval.\n- **Pharmacokinetic model:** Linear pharmacokinetics are assumed.\n- **Initial state (State 1, pre-ADA):** At steady state, the measured trough concentration is $C_{trough,1} = 7.20$ mg/L.\n- **Final state (State 2, post-ADA):** At steady state, after development of anti-drug antibodies (ADAs).\n- **Change in clearance:** Systemic clearance in State 2 ($CL_2$) is increased by $25\\%$ relative to baseline clearance in State 1 ($CL_1$).\n- **Invariants:** The dosing regimen (dose $D$ and dosing interval $\\tau$), bioavailability ($F$), and the \"within-interval concentration–time shape factor\" are unchanged.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded:** The problem is grounded in fundamental principles of clinical pharmacology and pharmacokinetics. The use of monoclonal antibodies as DMARDs, the development of anti-drug antibodies, and the consequent alteration of drug clearance are well-documented clinical phenomena. The concepts of steady state, clearance, bioavailability, and trough concentration are standard in the field.\n2.  **Well-Posed:** The problem is well-posed. It provides sufficient information to determine the new trough concentration. The relationship between steady-state concentration, clearance, and dosing is governed by fundamental pharmacokinetic equations. The invariance of the \"shape factor\" provides a direct link between the average and trough concentrations, which is key to the solution. A unique, stable, and meaningful solution exists.\n3.  **Objective:** The problem is stated in precise, objective language, using quantitative data and established terminology. It is free of subjective or opinion-based claims.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. It is scientifically sound, self-contained, and quantitatively defined. The solution process may proceed.\n\n### Solution\nThe solution is derived from the fundamental principles of steady-state pharmacokinetics.\n\nAt steady state, the rate of drug administration is equal to the rate of drug elimination when averaged over one dosing interval, $\\tau$. The average rate of administration for a drug given at a dose $D$ with a dosing interval $\\tau$ and bioavailability $F$ is $\\frac{F \\cdot D}{\\tau}$. The average rate of elimination is the product of the systemic clearance, $CL$, and the average steady-state plasma concentration, $C_{ss,avg}$.\n\nEquating these rates gives the mass-balance equation at steady state:\n$$CL \\cdot C_{ss,avg} = \\frac{F \\cdot D}{\\tau}$$\n\nThis equation can be rearranged to solve for the average steady-state concentration:\n$$C_{ss,avg} = \\frac{F \\cdot D}{CL \\cdot \\tau}$$\n\nThe problem states that a \"within-interval concentration–time shape factor\" links the trough concentration, $C_{trough}$, to the average steady-state concentration, $C_{ss,avg}$. Let us denote this dimensionless shape factor by $\\phi$. The relationship can be expressed as:\n$$C_{trough} = \\phi \\cdot C_{ss,avg}$$\nThe problem specifies that this factor $\\phi$ remains constant. This is a reasonable assumption if the development of ADAs increases the rate of elimination uniformly, without altering the shape of the concentration-time curve (e.g., by changing the volume of distribution or absorption rate constant, which were not mentioned).\n\nSubstituting the expression for $C_{ss,avg}$ into the equation for $C_{trough}$, we obtain:\n$$C_{trough} = \\phi \\cdot \\left(\\frac{F \\cdot D}{CL \\cdot \\tau}\\right)$$\n\nThis equation describes the relationship between the parameters at steady state. We can apply this equation to both the initial state (State 1, pre-ADA) and the final state (State 2, post-ADA).\n\nFor State 1:\n$$C_{trough,1} = \\phi \\cdot \\frac{F \\cdot D}{CL_1 \\cdot \\tau}$$\n\nFor State 2:\n$$C_{trough,2} = \\phi \\cdot \\frac{F \\cdot D}{CL_2 \\cdot \\tau}$$\n\nTo find the new trough concentration, $C_{trough,2}$, we can take the ratio of the two equations. The terms $F$, $D$, $\\tau$, and $\\phi$ are stated to be constant and will cancel.\n$$\\frac{C_{trough,2}}{C_{trough,1}} = \\frac{\\phi \\cdot \\frac{F \\cdot D}{CL_2 \\cdot \\tau}}{\\phi \\cdot \\frac{F \\cdot D}{CL_1 \\cdot \\tau}} = \\frac{CL_1}{CL_2}$$\n\nThis shows that the steady-state trough concentration is inversely proportional to the systemic clearance, a core principle of linear pharmacokinetics when dosing is held constant.\n\nThe problem states that the systemic clearance in State 2 ($CL_2$) is increased by $25\\%$ relative to the baseline clearance in State 1 ($CL_1$). This can be written as:\n$$CL_2 = CL_1 + (0.25 \\cdot CL_1) = (1 + 0.25) \\cdot CL_1 = 1.25 \\cdot CL_1$$\n\nNow, we substitute this relationship into our ratio equation:\n$$\\frac{C_{trough,2}}{C_{trough,1}} = \\frac{CL_1}{1.25 \\cdot CL_1} = \\frac{1}{1.25}$$\n\nWe can now solve for $C_{trough,2}$:\n$$C_{trough,2} = C_{trough,1} \\cdot \\frac{1}{1.25}$$\n\nThe initial trough concentration is given as $C_{trough,1} = 7.20$ mg/L. Substituting this value:\n$$C_{trough,2} = (7.20 \\text{ mg/L}) \\cdot \\frac{1}{1.25}$$\n$$C_{trough,2} = (7.20 \\text{ mg/L}) \\cdot 0.8$$\n$$C_{trough,2} = 5.760 \\text{ mg/L}$$\n\nThe problem requires the final answer to be rounded to three significant figures, consistent with the precision of the input value $7.20$ mg/L. The calculated value is $5.760$. Rounding to three significant figures gives $5.76$.", "answer": "$$\\boxed{5.76}$$", "id": "4531849"}]}